Zoetis
About: Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Employees: 14,100
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
33% more first-time investments, than exits
New positions opened: 153 | Existing positions closed: 115
14% more funds holding in top 10
Funds holding in top 10: 22 [Q2] → 25 (+3) [Q3]
13% more repeat investments, than reductions
Existing positions increased: 719 | Existing positions reduced: 635
6% more capital invested
Capital invested by funds: $75.6B [Q2] → $80.4B (+$4.78B) [Q3]
2% more funds holding
Funds holding: 1,706 [Q2] → 1,744 (+38) [Q3]
3% less call options, than puts
Call options by funds: $221M | Put options by funds: $228M
3.4% less ownership
Funds ownership: 95.67% [Q2] → 92.27% (-3.4%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
UBS | 19%upside $196 | Neutral Initiated | 9 Dec 2024 |
Leerink Partners Daniel Clark 0% 1-year accuracy 0 / 2 met price target | 30%upside $215 | Outperform Initiated | 2 Dec 2024 |
JP Morgan Chris Schott 24% 1-year accuracy 4 / 17 met price target | 40%upside $230 | Overweight Maintained | 11 Oct 2024 |
Financial journalist opinion
Based on 14 articles about ZTS published over the past 30 days
